ESTRO 2022 - Abstract Book

S1096

Abstract book

ESTRO 2022

Conclusion Liver SBRT is safe and is related with only moderate morbidity to the patients. Leukopenia and thrombocytopenia is observed mainly during the course of radiation, which normalizes till 1 month of treatment. AFP levels shows a rise initially and start to decrease till 1 month after radiation unlike PIVKA II which tends to fall at the commencement of radiation.

PO-1299 Charlson Comorbidity Index for patients selection in definitive chemoradiation for anal carcinoma

S. Lucidi 1 , A. Romei 1 , N. Bertini 1 , M. Loi 2 , P. Bonomo 2 , I. Desideri 3 , V. Di Cataldo 4 , B. Detti 3 , M. Casati 5 , M. Zani 5 , C. Arilli 5 , V. Salvestrini 1 , M. Roghi 1 , M. Aquilano 1 , M. Ganovelli 1 , M. Banini 1 , M. Valzano 1 , C. Bellini 1 , I. Meattini 1 , L. Livi 1 1 University of Florence, Departments of Biomedical, Experimental, and Clinical Sciences ''M. Serio'', Florence, Italy; 2 Careggi University Hospital, Radiation Oncology , Florence, Italy; 3 Careggi University Hospital, Radiation Oncology, Florence, Italy; 4 Florentine Institute of Care and Assistance, IFCA Radiotherapy and Medical Physics Unit, Florence, Italy; 5 Careggi University Hospital, Department of Medical Physics, Florence, Italy Purpose or Objective The standard of care for the curative treatment of squamous cell carcinoma of the anal canal (SCCAC), is definitive chemoradiation (CRT): however, this treatment may be burdened with severe side effects, and some patients may not be able to complete the planned treatment. In order to tailor the optimal treatment intensity, criteria for patients selection are needed to identify those who may achieve the largest benefit from CRT, whereas avoiding undue toxicity in frail subjects. The aim of our study is to evaluate prognostic variables correlated with clinical outcomes in patients treated with CRT. Materials and Methods A consecutive cohort of patients with SCCAC treated with Simultaneous Integrated Boost – Intensity Modulated Radiation Therapy (SIB-IMRT) in our institution between 2014 and 2018 was analyzed. Clinical information including age-adjusted Charlson Comorbidity Index (CCI), treatment schedule and dosimetric data were collected. Endpoints were Progression- Free Survival (PFS), Cancer-Specific Survival (CSS) and Overall Survival (OS). Statistical analysis was performed to correlate clinical and treatment-related variables with outcomes. Results Fifty-two patients were included in our analysis: 15 (29%) patients were men and 36 (71%) were women. Median age was 66 years (range 39-86 years). Fourteen patients (27%) had a CCI > 5. Disease stage was > 3 in 17 (33%) patients. Median size of PTV receiving 55 Gy (PTV 1) was 250cc. All patients achieved treatment completion to a final dose of 55 Gy in 2.2 Gy/fraction to the tumor and involved lymph nodes and 45 Gy in 1.8Gy/fraction to elective drainages in 25 fractions. Thirty- six patients (70%) received concurrent chemotherapy. At a median follow-up of 50 months (range 5-109 months), 6 (12%) and 14 (27%) patients died of disease progression and non-cancer-related events, respectively. No treatment-related deaths were observed. The 3-year PFS, CSS and OS rates were 74%, 89% and 82%, respectively (Fig.1). Nodal staging > 2 and PTV 1 size >250cc were correlated with worse PFS at univariate analysis (p=0.0013 and p= 0.0194, respectively), although only nodal staging > 2 at the multivariate analysis was confirmed as statistically significant (p= 0.023). Stage III disease negatively impacted CSS (p=0.02). Overall, only a CCI > 5 had an impact on OS (p= 0.023) (Fig.2).